×
AleAnna EBITDA 2022-2024 | ANNA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
AleAnna ebitda from 2022 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
AleAnna EBITDA 2022-2024 | ANNA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
AleAnna ebitda from 2022 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$73.4B
Chugai Pharmaceutical (CHGCY)
$72.5B
Takeda Pharmaceutical (TAK)
$42.2B
Merck (MKKGY)
$18.5B
Sandoz Group AG (SDZNY)
$17.9B
Astellas Pharma (ALPMY)
$17.4B
United Therapeutics (UTHR)
$16.1B
Neurocrine Biosciences (NBIX)
$14B
Summit Therapeutics (SMMT)
$13.5B
Shionogi (SGIOY)
$11.9B
Madrigal Pharmaceuticals (MDGL)
$6.8B
Orion OYJ (ORINY)
$6.2B
Ionis Pharmaceuticals (IONS)
$5.5B
Corcept Therapeutics (CORT)
$5.2B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.5B
Recursion Pharmaceuticals (RXRX)
$2.8B
Dyne Therapeutics (DYN)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
NewAmsterdam Pharma (NAMS)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.3B
Soleno Therapeutics (SLNO)
$2B
Indivior (INDV)
$1.7B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Evotec AG (EVO)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B
Harrow (HROW)
$1.3B
Guardian Pharmacy Services (GRDN)
$1.3B